Ken Griffin A Tyr Pharma Inc Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$1.51 - $2.24 $2,265 - $3,360	-1,500 Reduced 32.61%	3,100 $5,000
Q2 2024 Aug 14, 2024	BUY	$0.0 - $2.07 $0 - $2,898	1,400 Added 43.75%	4,600 $7,000
Q1 2024 May 15, 2024	BUY	$1.42 - $2.02 $3,834 - $5,454	2,700 Added 540.0%	3,200 $6,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $1.51 $3,330 - $4,530	-3,000 Reduced 85.71%	500 $0
Q3 2023 Nov 14, 2023	SELL	$1.55 - $2.23 $15,500 - $22,300	-10,000 Reduced 74.07%	3,500 $5,000
Q2 2023 Aug 14, 2023	BUY	$1.72 - $2.57 $17,716 - $26,471	10,300 Added 321.88%	13,500 $29,000
Q1 2023 May 15, 2023	BUY	$1.88 - $2.5 $2,256 - $3,000	1,200 Added 60.0%	3,200 $6,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $2.49 $4,040 - $4,980	2,000 New	2,000 $4,000

37.1M

30.2K

3.1K

Ticker LIFE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,625,000
Market Cap $53.2M
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.